Synthesis of the E ring of salinomycin : a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy at Massey University

Thumbnail Image
Open Access Location
Journal Title
Journal ISSN
Volume Title
Massey University
The synthesis of (2R*, 5R*, 2'S*) and (2S*, 5R*, 2'S*)-2-(iodomethyl)-5-(2'-methyltetrahydrofur-2'-yl)tetrahydrofurans 331a, 331b in a 5:1 ratio by the iodoetherification of (1R*, 2'S*)-1-(2'-methyltetrahydrofur-2'-yl)-4-penten-1-ol 330a is described. Subsequent iodoetherification of ether derivatives 385 - 389 of hydroxyalkene 330a was then effected to produce predominantly the cis iodide 331b. (1R*, 2'S*)-1-(2'-methyltetrahydrofur-2'-yl)-1-(2", 6"-dichlorobenzyloxy)-4-pentene 387 proved most successful in this respect affording iodides 331a, 331b in a 1:10 ratio. Attempted silver catalysed ring expansion of iodide 331a proved ineffective affording only (5R*, 2'S*)-5-(2'-methyltetrahydro-2'-yl)-5-hydroxypentan-2-one 344. The synthesis of (E)-1-bromo-3-ethyl-3-pentene 146 is described, the key step in its formation being the diastereoselective reaction of 2-ethyl-1-butene 364 with butyl glyoxylate 367, in the presence of a titanium catalyst formed in situ from diisopropoxytitanium(VI) dichloride 362 and (±)-1,1'-bi-2-naphthol 363, to afford butyl (E)-4-ethyl-2-hydroxy-4-hexenoate 370. The synthesis of (2S*, 3R*, 6R*, 2'S*)-3-ethyl-3-hydroxy-2-methyl-6-(2'-methyltetrahydrofur-2'-yl)tetrahydropyran 323 from 2-methyl-2-tetrahydrofuraldehyde 322 is described, thereby modelling the synthesis of the E ring of salinomycin. The synthesis began with the coupling of the organolithium derivative of (E)-1-bromo-3-ethyl-3-pentene 146 to 2-methyl-2-tetrahydrofuraldehyde 322 to afford (4E, 1R*, 2'S*)- and (4E, 1S*, 2'S*)-4-ethyl-1-(2'-methyltetrahydrofur-2'-yl)-4-hexen-1-ol 348a, 348b in a 3:1 ratio. Following separation of the alcohols 348a, 348b via formation of their acetate derivatives 383a, 383b, iodoetherification of (4E, 1R*, 2'S*)-4-ethyl-1-(2'-methyltetrahydrofur-2'-yl)-4-hexen-1-ol 348a afforded (2R*, 5R*, 1'S*, 2"S*)- and (2S*, 5R*, 1'R*, 2"S*)-2-ethyl-2-(1'-iodoethyl)-5-(2"-methyltetrahydrofur-2"-yl)tetrahydrofurans 347a and 347b in a 3:1 ratio. Subsequent ring expansion of iodide 347b resulted in formation of the target pyran 323 in 77% yield. Iodoetherification of the trimethylsilyl derivative 392 of (4E, 1R*, 2'S*)-4-ethyl-1-(2'-methyltetrahydrofur-2'-yl)-4-hexen-1-ol 348a produced the iodides 347a and 347b in a 1:1 ratio, while the 2,6-dichlorobenzyl 390 and 4-bromobenzyl 391 derivatives were too sterically hindered for iodoetherification to occur.
Salinomycin, Antibiotics